Xenon Pharmaceuticals Inc
For the period ended Mar 31, 2025. Filed May 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
(a) Exhibits.
| Exhibit · Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Number | Description of Document | Form | File No. | Exhibit | Filing Date |
| 3.1 | Articles of the Company. | 10-Q | 001-36687 | 3.1 | December 15, 2014 |
| 3.1A | Articles of Amendment to the Articles of the Company, creating the Series 1 Preferred Shares. | 8-K | 001-36687 | 3.1 | March 28, 2018 |
| 3.2 | Amended and Restated By-laws of the Company. | 10-Q | 001-36687 | 3.2 | December 15, 2014 |
| 10.1 | Letter Agreement, dated January 15, 2025, by and between the Company and Christopher Von Seggern. | 10-K | 001-36687 | 10.30 | February 27, 2025 |
| 10.2 | Consulting Agreement, dated January 17, 2025, by and between the Company and Christopher Von Seggern. | 10-K | 001-36687 | 10.31 | February 27, 2025 |
| 10.3 | 2025 Inducement Equity Incentive Plan and related form agreements. | 10-K | 001-36687 | 10.32 | February 27, 2025 |
| 10.4 | Post-Employment Consulting Agreement, dated February 27, 2025, by and between the Company and Sherry Aulin. | 10-K | 001-36687 | 10.33 | February 27, 2025 |
| 10.5 | Form of Restricted Share Unit Award Agreement. | ||||
| 10.6 | Form of Performance Share Unit Award Agreement. | ||||
| 31.1 | Certification of Chief Executive Officer pursuant to Rule 13a-14(a). | ||||
| 31.2 | Certification of Chief Financial Officer pursuant to Rule 13a-14(a). | ||||
| 32.1* | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350. | ||||
| 32.2* | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350. | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document with Embedded Linkbases Document | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
*The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Xenon Pharmaceuticals Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
-64-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.